Osimertinib treatment did not significantly change the number of PD-L1+ or pS6+ CTCs, implying that this distinct (EGFR–PI3K–AKT–mTOR–S6) pathway is constantly activated in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.